Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:activeDuring |
paliperidone
|
| gptkbp:brand |
gptkb:Invega
|
| gptkbp:clinicalTrials |
Phase III
NICE guidelines APA guidelines acute treatment maintenance treatment |
| gptkbp:contraindication |
seizures
severe renal impairment hyperglycemia hypersensitivity to paliperidone neuroleptic malignant syndrome tardive dyskinesia |
| gptkbp:date |
2010-10-29
|
| gptkbp:diseaseResistance |
available
|
| gptkbp:dosageForm |
suspension
|
| gptkbp:drugInterdiction |
prescription only
|
| gptkbp:formulation |
long-acting injectable
|
| gptkbp:frequency |
once a month
|
| gptkbp:hasPopulation |
adults
adolescents |
| gptkbp:healthcare |
lifestyle modifications
recognizing side effects importance of adherence regular follow-up appointments |
| gptkbp:historical_analysis |
safety profile
long-term efficacy comparative effectiveness |
| https://www.w3.org/2000/01/rdf-schema#label |
Invega Sustenna
|
| gptkbp:is_monitored_by |
weight
renal function blood glucose lipid levels |
| gptkbp:launchSite |
deltoid muscle
gluteal muscle |
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:marketSegment |
available
|
| gptkbp:notableFeature |
gptkb:Invega
Abilify Seroquel Risperdal |
| gptkbp:numberOfStudents |
approximately 25-49 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:offers |
varies by location
|
| gptkbp:packaging |
single-dose vial
|
| gptkbp:regulatoryCompliance |
FDA_approved
|
| gptkbp:route |
intramuscular injection
|
| gptkbp:sideEffect |
drowsiness
weight gain increased cholesterol extrapyramidal symptoms |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist |
| gptkbp:usedFor |
treatment of schizoaffective disorder
treatment of schizophrenia |